Latest news with #VenusRemedies
Business Standard
27-05-2025
- Business
- Business Standard
Venus Remedies spurts after Q4 PAT climbs 100% YoY to Rs 21 cr
Venus Remedies soared 11.86% to Rs 405.20 after the company reported a 99.80% surge in consolidated net profit to Rs 21 crore in Q4 FY25 as against Rs 10.51 crore recorded in Q4 FY24. However, revenue from operations decreased marginally to Rs 194.97 crore in Q4 FY25, as against Rs 195.16 crore posted in the corresponding quarter of the previous year. Profit before tax surged 77.57% to Rs 31.04 crore in Q4 FY25, compared to Rs 17.48 crore in Q4 FY24. Total expenses slipped 6.01% YoY to Rs 170.69 crore in Q4 FY25. The cost of materials consumed was Rs 104.21 crore (up 23.80% YoY), while employee benefits expenses stood at Rs 21.16 crore (up 7.35% YoY) during the March 2025 quarter. During Q4 FY25, EBITDA stood at Rs 35.77 crore, up 52.92% from Rs 23.39 crore posted in the corresponding quarter last year. On a full-year basis, the company's consolidated net profit surged 59.07% to Rs 45.32 crore on a 7.72% jump in revenue from operations to Rs 647.89 crore in FY25 over FY24. Venus Remedies is an Indian research-driven pharmaceutical company dedicated to developing innovative solutions to improve patient outcomes.
Business Standard
27-05-2025
- Business
- Business Standard
Venus Remedies consolidated net profit rises 99.81% in the March 2025 quarter
Sales decline 0.10% to Rs 194.97 crore Net profit of Venus Remedies rose 99.81% to Rs 21.00 crore in the quarter ended March 2025 as against Rs 10.51 crore during the previous quarter ended March 2024. Sales declined 0.10% to Rs 194.97 crore in the quarter ended March 2025 as against Rs 195.16 crore during the previous quarter ended March 2024. For the full year,net profit rose 59.13% to Rs 45.32 crore in the year ended March 2025 as against Rs 28.48 crore during the previous year ended March 2024. Sales rose 7.72% to Rs 647.89 crore in the year ended March 2025 as against Rs 601.45 crore during the previous year ended March 2024. Particulars Quarter Ended Year Ended Mar. 2025 Mar. 2024 % Var. Mar. 2025 Mar. 2024 % Var. Sales 194.97195.16 0 647.89601.45 8 OPM % 14.879.98 - 9.819.91 - PBDT 35.7523.37 53 84.4371.09 19 PBT 31.0417.46 78 61.9244.64 39 NP 21.0010.51 100 45.3228.48 59
Time of India
24-05-2025
- Business
- Time of India
Venus Remedies gets Ukrainian GMP renewal certification
Pharma major Venus Remedies on Saturday said it has successfully renewed its good manufacturing practices (GMP) certification from Ukraine's State Service on Medicines and Drugs Control (SMDC). The certification applies to the company's Unit-II manufacturing facility located in Baddi, Himachal Pradesh, covering its cephalosporin, non-cephalosporin (carbapenem), and oncology parenteral production lines, including liquid and lyophilized injections, Venus Remedies said in a statement. "Renewal of the Ukrainian GMP certification underlines our unwavering commitment to maintaining world-class manufacturing standards. This milestone not only reinforces our foothold in the Ukrainian market but also facilitates deeper penetration into PIC/S markets, significantly enhancing our international growth prospects," Venus Remedies President, Global Critical Care, Saransh Chaudhary said. Ukraine, being a member of the Pharmaceutical Inspection Co-operation Scheme (PIC/S) consortium, comprising 56 countries spanning Europe, Asia, Oceania, and the Americas, further amplifies the global acceptance and strategic importance of this certification. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like ansoim - Manufacturing Today OMEA Award for Indian Manufacturers ansoim Learn More Undo Venus Remedies already has a robust presence in 32 PIC/S countries , including South Africa, Thailand, Malaysia, Saudi Arabia, and Australia, with plans for continued expansion, it said. The Ukrainian pharmaceutical market, projected to grow at a CAGR (compound annual growth rate) of 3.9 per cent and reach USD 822.26 million by 2029, is driven largely by increased demand for generics and oncology treatments . Live Events Venus Remedies, with over two decades of experience in Ukraine and 44 product registrations to date, views this certification as pivotal for sustained growth and expanded access within the broader Asia Commonwealth of Independent States (CIS) region. Aditi K Chaudhary, President, International Business, Venus Remedies Ltd, said, "Ukraine continues to be a key strategic market for us. This renewed GMP certification enhances our credibility with regulators and partners across the region, enabling us to deepen our market presence, expand product portfolios, and provide high-quality medicines to a wider patient base".
&w=3840&q=100)
Business Standard
24-05-2025
- Business
- Business Standard
Venus Remedies gets GMP renewal certification from Ukraine's SMDC
Pharma major Venus Remedies on Saturday said it has successfully renewed its good manufacturing practices (GMP) certification from Ukraine's State Service on Medicines and Drugs Control (SMDC). The certification applies to the company's Unit-II manufacturing facility located in Baddi, Himachal Pradesh, covering its cephalosporin, non-cephalosporin (carbapenem), and oncology parenteral production lines, including liquid and lyophilized injections, Venus Remedies said in a statement. "Renewal of the Ukrainian GMP certification underlines our unwavering commitment to maintaining world-class manufacturing standards. This milestone not only reinforces our foothold in the Ukrainian market but also facilitates deeper penetration into PIC/S markets, significantly enhancing our international growth prospects," Venus Remedies President, Global Critical Care, Saransh Chaudhary said. Ukraine, being a member of the Pharmaceutical Inspection Co-operation Scheme (PIC/S) consortium, comprising 56 countries spanning Europe, Asia, Oceania, and the Americas, further amplifies the global acceptance and strategic importance of this certification. Venus Remedies already has a robust presence in 32 PIC/S countries, including South Africa, Thailand, Malaysia, Saudi Arabia, and Australia, with plans for continued expansion, it said. The Ukrainian pharmaceutical market, projected to grow at a CAGR (compound annual growth rate) of 3.9 per cent and reach USD 822.26 million by 2029, is driven largely by increased demand for generics and oncology treatments. Venus Remedies, with over two decades of experience in Ukraine and 44 product registrations to date, views this certification as pivotal for sustained growth and expanded access within the broader Asia Commonwealth of Independent States (CIS) region. Aditi K Chaudhary, President, International Business, Venus Remedies Ltd, said, "Ukraine continues to be a key strategic market for us. This renewed GMP certification enhances our credibility with regulators and partners across the region, enabling us to deepen our market presence, expand product portfolios, and provide high-quality medicines to a wider patient base". (Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
